HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.
HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.